|
|
Volumn 26, Issue 6, 2012, Pages 414-422
|
|
Pharmacogenetic influence of LOC387715/HTRA1 on the efficacy of bevacizumab treatment for age-related macular degeneration in a Korean population.
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANGIOGENESIS INHIBITOR;
BEVACIZUMAB;
DNA;
HTRA1 PROTEIN, HUMAN;
MONOCLONAL ANTIBODY;
SERINE PROTEINASE;
VASCULOTROPIN A;
AGED;
ALLELE;
ARTICLE;
COMPARATIVE STUDY;
COMPLEMENT FACTOR H Y402H;
DRUG ANTAGONISM;
FEMALE;
FOLLOW UP;
GENETIC POLYMORPHISM;
GENETICS;
GENOTYPE;
HTRA1;
HUMAN;
INTRAVITREAL DRUG ADMINISTRATION;
LOC387715;
MALE;
METABOLISM;
METHODOLOGY;
PHARMACOGENETICS;
RETINA MACULA DEGENERATION;
RETROSPECTIVE STUDY;
VISUAL ACUITY;
BEVACIZUMAB;
COMPLEMENT FACTOR H Y402H;
HTRA1;
LOC387715;
MACULAR DEGENERATION;
AGED;
ALLELES;
ANGIOGENESIS INHIBITORS;
ANTIBODIES, MONOCLONAL, HUMANIZED;
DNA;
FEMALE;
FOLLOW-UP STUDIES;
GENOTYPE;
HUMANS;
INTRAVITREAL INJECTIONS;
MACULAR DEGENERATION;
MALE;
PHARMACOGENETICS;
POLYMORPHISM, GENETIC;
RETROSPECTIVE STUDIES;
SERINE ENDOPEPTIDASES;
VASCULAR ENDOTHELIAL GROWTH FACTOR A;
VISUAL ACUITY;
|
|
EID: 84891681426
PISSN: 10118942
EISSN: None
Source Type: Journal
DOI: 10.3341/kjo.2012.26.6.414 Document Type: Article |
|
Times cited : (15)
|
|
References (0)
|
